Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07392190 · ClinicalTrials.gov registry record · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
- 20
- Study locations
NCT07392190 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 900 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT07392190, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eloralintide
Study Locations (20)
California
- Irvine Clinical Research - Irvine
- Scripps Whittier Diabetes Institute - La Jolla
- Peninsula Research Associates - Rolling Hills Estates
- Care Access - Sacramento - Sacramento
- Artemis Institute for Clinical Research - San Diego
- Southern California Clinical Research - Santa Ana
- University Clinical Investigators, Inc. - Tustin
Florida
- JEM Research Institute - Atlantis
- AMR Clinical - Doral
- Northeast Research Institute (NERI) - Fleming Island
- Jacksonville Center for Clinical Research - Jacksonville
- New Horizon Research Center - Miami
- St Johns Center for Clinical Research - Saint Augustine
Arizona
- RIO Clinical Trials - Phoenix - Phoenix
- Headlands Research - Scottsdale - Scottsdale
- Novak Clinical Research - Tucson - North La Cholla Boulevard - Tucson
Connecticut
- New England Research Associates, LLC - Bridgeport
- Yale University School of Medicine - New Haven
- Chase Medical Research, LLC - Waterbury
Alabama
- Birmingham Clinical Research - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07392190
The ClinicalTrials.gov registry entry for NCT07392190 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (10% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07392190 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07392190 about?
NCT07392190 is a clinical study titled "A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin". The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
What is the current status of trial NCT07392190?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2026-02-10. Estimated completion is 2028-07.
What conditions does trial NCT07392190 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07392190?
The interventions under investigation include: Placebo (DRUG), Eloralintide (DRUG).
Who is sponsoring clinical trial NCT07392190?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07392190 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.